MK-677 (Ibutamoren) Liver Function Impact: What the Clinical Evidence Actually Shows

What MK-677 Does Inside the Liver

MK-677 does not act on the liver directly in the way a classical hepatotoxin does. It binds the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, amplifying pulsatile growth hormone secretion. That rise in circulating GH then reaches hepatocytes, where it activates GH receptors and drives synthesis of insulin-like growth factor-1 (IGF-1). The liver is therefore the primary production site for the IGF-1 elevation that users seek. [1]

The GH-IGF-1 Axis and Hepatocyte Workload

GH receptor signaling in the liver runs through the JAK2/STAT5b pathway. Each pulsatile GH surge triggers STAT5b phosphorylation, which drives transcription of the IGF-1 gene. Murphy et al. (J Clin Endocrinol Metab, 1998; N=32) demonstrated that a single oral dose of 25 mg MK-677 produced sustained 24-hour elevation of both GH pulse amplitude and serum IGF-1, with IGF-1 rising roughly 60% above baseline. [2] That sustained signal means hepatocytes are running JAK2/STAT5b cascades more continuously than they would under physiological GH pulsatility.

Why Continuous Signaling Matters

Physiological GH is released in sharp, short pulses separated by periods of near-zero serum GH. Sustained GH exposure, as seen in acromegaly, is associated with hepatic steatosis, insulin resistance, and altered lipid metabolism. MK-677 does not replicate acromegaly-level GH, but it does blunt the normal off-periods. Whether that partial blunting is enough to shift hepatic fat metabolism is an open question that the existing trial data do not fully resolve. [3]

What Controlled Trials Actually Report About Liver Enzymes

The direct hepatotoxicity signal in RCT data is reassuringly low. No published placebo-controlled trial of MK-677 at doses of 10 to 25 mg/day has reported a statistically significant rise in ALT, AST, alkaline phosphatase, or total bilirubin compared with placebo. However, the clinical trial population has been narrow, the longest trial ran only 24 months, and none of the trials was designed with hepatic histology as a primary endpoint. [4]

The Nass 2008 Twenty-Four-Month Trial

Nass et al. (J Clin Endocrinol Metab, 2008; N=65) randomized older adults (mean age 69 years) to MK-677 25 mg or placebo for 24 months and measured IGF-1, body composition, and safety labs at regular intervals. The authors reported no significant change in liver enzymes across the treatment period. Fat-free mass increased by approximately 1.5 kg in the active arm, and fasting blood glucose rose modestly (a mean of ~0.19 mmol/L). [4] Liver function tests were reported as a safety endpoint rather than a primary outcome, meaning any sub-threshold enzymatic shifts would not have been statistically powered for detection.

The Older Frailty Trials

A separate randomized trial in elderly hip-fracture patients (Adunsky et al., 2011; N=123) found similar results: no hepatotoxicity signal at 25 mg/day over 24 weeks. [5] That population carries higher baseline liver-disease prevalence than healthy volunteers, which makes the clean safety signal marginally more informative. ALT and AST remained within normal limits in both treatment and placebo arms.

Gaps in the Evidence Base

The trials above share three structural limitations. First, none enrolled patients with pre-existing non-alcoholic fatty liver disease (NAFLD) or elevated baseline transaminases. Second, liver imaging (ultrasound or MRI-PDFF for hepatic fat quantification) was not performed. Third, no trial exceeded 24 months. Given that many current users take MK-677 for longer periods and at higher doses than were studied, the clean trial record is a starting point, not a clearance.

Mechanisms That Could Indirectly Harm the Liver

Insulin Resistance and Hepatic Fat

GH is a counter-regulatory hormone. Chronically elevated GH exposure reduces insulin sensitivity in peripheral tissues and in the liver itself. Nass et al. Explicitly noted the modest rise in fasting glucose. [4] In the liver, reduced insulin sensitivity impairs suppression of de novo lipogenesis and hepatic glucose output. Over months to years, this could contribute to hepatic fat accumulation in genetically susceptible individuals or in those who are already overweight.

The 2023 ADA Standards of Care note that insulin resistance is a primary driver of NAFLD progression to non-alcoholic steatohepatitis (NASH). [6] MK-677 users who already have metabolic syndrome or a BMI above 30 may carry meaningful hepatic risk even if their transaminases remain normal, because steatosis can precede ALT elevation by years.

IGF-1 and Hepatocellular Proliferation Signaling

High IGF-1 activates PI3K/Akt/mTOR pathways that promote cell growth. In healthy liver parenchyma, this is largely benign over short periods. In tissue with pre-existing dysplastic change or chronic hepatitis B or C infection, however, sustained IGF-1 elevation could theoretically accelerate hepatocellular transformation. The clinical hepatology literature has documented that serum IGF-1 is elevated in some early hepatocellular carcinoma studies, though the direction of causality is contested. [7] No trial has examined MK-677 in patients with viral hepatitis, and this population should be considered a contraindication until evidence is available.

Drug Metabolism and CYP Interactions

MK-677 is primarily metabolized via CYP3A4. Hepatic CYP3A4 activity accounts for roughly 30% of hepatic oxidative drug metabolism overall. In theory, co-administration with strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) could raise MK-677 plasma levels and extend receptor saturation, compounding GH pulsatility distortion. Co-administration with CYP3A4 inducers (rifampin, carbamazepine) could reduce efficacy. No formal drug-interaction trial has been published for MK-677. The FDA's guidance on CYP3A4 substrates recommends caution with any agent whose therapeutic window has not been formally characterized. [8]

The Gray Zone: Supplement Contamination and Off-Label Stacking

MK-677 is sold widely as a "research chemical" or "dietary supplement," categories that receive no pre-market efficacy or safety review from the FDA. The FDA has issued multiple warning letters to companies marketing SARMs and research peptides as supplements. [9] Contamination with hepatotoxic compounds, including anabolic-androgenic steroids that are well-documented causes of drug-induced liver injury (DILI), is a documented risk in this product category.

Anabolic Steroid Co-Use

A large fraction of self-reported MK-677 users on pharmacology forums describe co-administering anabolic steroids, selective androgen receptor modulators (SARMs such as LGD-4033 or RAD-140), or other peptides. Anabolic steroids cause cholestatic hepatitis, peliosis hepatis, and hepatocellular adenoma at measurable rates. When transaminase elevation occurs in someone co-using MK-677 and an oral anabolic steroid, attributing causality to MK-677 alone is impossible without dechallenge-rechallenge data. The LiverTox database maintained by the NIH lists anabolic steroids as a category A hepatotoxin (definite cause of clinical liver injury). [10]

What This Means for Risk Attribution

Most anecdotal reports of liver injury in MK-677 users do not meet the Roussel-Uclaf Causality Assessment Method (RUCAM) threshold for probable or definite attribution because polypharmacy and unverified product purity confound every case. Clinicians evaluating a patient with elevated transaminases who discloses MK-677 use should obtain a complete medication and supplement history and apply RUCAM before attributing injury to ibutamoren.

Monitoring Protocol for Patients Who Disclose MK-677 Use

No professional guideline body has published a monitoring protocol specific to MK-677, because the compound is not approved for clinical use. The framework below is based on GH-axis physiology, the safety labs used in published trials, and general DILI surveillance principles from the American College of Gastroenterology.

Baseline Assessment (Before Starting or at First Disclosure)

A baseline panel should include: ALT, AST, alkaline phosphatase, total and direct bilirubin, GGT, fasting glucose, fasting insulin (to calculate HOMA-IR), serum IGF-1, and a lipid panel. A hepatic ultrasound is reasonable if the patient has a BMI above 28 or any features of metabolic syndrome, because steatosis at baseline changes the risk-benefit calculus significantly.

Clinicians should also screen for chronic hepatitis B surface antigen and hepatitis C antibody if not recently tested. As noted above, chronic viral hepatitis combined with pharmacologically elevated IGF-1 is a combination without adequate safety data.

On-Treatment Monitoring

The monitoring intervals below mirror those used in published MK-677 trials, adapted for a higher-risk outpatient population.

• Weeks 4 to 8: Repeat ALT, AST, fasting glucose, serum IGF-1. Dose should be reassessed if ALT or AST exceeds three times the upper limit of normal (3x ULN) on two measurements taken at least one week apart.
• Every 3 months thereafter: Full LFT panel plus fasting glucose and IGF-1.
• At 12 months: Consider hepatic ultrasound if any of the following are present: fasting glucose increase of more than 0.5 mmol/L from baseline, IGF-1 above age-adjusted upper limit of normal, or new-onset insulin resistance (HOMA-IR above 2.5).

Stopping Rules

Discontinue immediately if ALT or AST exceeds five times ULN, if jaundice or right-upper-quadrant pain develops, or if bilirubin rises above two times ULN in the absence of Gilbert syndrome. These thresholds align with the "Hy's Law" criteria used by the FDA to identify drugs with potential for serious hepatotoxicity. [8]

How MK-677 Compares to Other GH-Axis Interventions on Liver Safety

Recombinant human growth hormone (rhGH), which produces a comparable IGF-1 response through daily subcutaneous injection, has a substantially larger safety dataset. Long-term rhGH registries including the KIGS (Pfizer International Growth Database, N over 73,000 patient-years) and the Hypopituitary Control and Complications Study (HypoCCS) have not identified a hepatotoxicity signal at replacement doses. [3] That is reassuring but not directly transferable to MK-677, because oral bioavailability, receptor selectivity, pulsatility kinetics, and the presence of non-GHSR off-target effects differ between the two compounds.

Sermorelin, a GHRH analog, produces GH elevation through a different receptor (GHRHR rather than GHSR-1a) and similarly lacks a documented hepatotoxicity signal in clinical use, though its dataset is smaller. Neither sermorelin nor rhGH carries the product-purity concerns inherent to unregulated research-chemical sourcing.

Special Populations With Elevated Hepatic Risk

Patients With Pre-Existing Liver Disease

Any patient with known cirrhosis, portal hypertension, or Child-Pugh class B or C liver disease should not use MK-677. GH signaling is already dysregulated in cirrhosis; hepatic IGF-1 production is characteristically reduced (not elevated) in cirrhotic patients because of GH resistance at the receptor level. Trying to force-raise IGF-1 through supraphysiological GHSR agonism in a fibrotic liver adds unpredictable metabolic load to an organ with compromised synthetic reserve. [7]

Patients With Type 2 Diabetes

The modest glucose rise documented by Nass et al. [4] becomes clinically relevant in patients already managing hyperglycemia. Elevated GH worsens hepatic insulin resistance, which can raise fasting glucose, aggravate hepatic fat accumulation, and accelerate NAFLD progression. Patients on metformin or GLP-1 receptor agonists may partially offset this effect, but no study has examined this combination directly.

Adolescents

Several online sources promote MK-677 to adolescents for height gain. Age <18 is a clear contraindication based on unpredictable growth-plate effects and the absence of any safety data in developing livers. The FDA has explicitly warned that unapproved GH secretagogues should not be used in minors. [9]

Interpreting Liver Enzyme Results in the Clinical Setting

Transaminase elevation in an MK-677 user is almost never straightforward. A rise in ALT up to 2x ULN in a patient who has recently started resistance training can reflect skeletal muscle injury rather than hepatocellular damage. Concurrent protein supplementation with casein, whey, or creatine does not cause liver injury at standard doses, but high-dose creatine (above 20 g/day in loading phases) has occasionally produced transient ALT elevation in case reports.

Obtaining an LDH, creatine kinase (CK), and GGT alongside the standard LFT panel helps differentiate hepatocellular injury (ALT and GGT both elevated) from muscle injury (CK elevated, GGT normal) from cholestasis (alkaline phosphatase and bilirubin elevated). If the pattern is hepatocellular and RUCAM scoring implicates MK-677 or a co-administered compound, the appropriate response is to stop the compound, repeat LFTs in two to four weeks, and refer to hepatology if the trend does not resolve.

Clinical Consensus on Ongoing Use

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states: "We recommend against the use of GH secretagogues in clinical practice outside of approved indications and controlled research settings." [11] That recommendation is not specifically about liver toxicity; it reflects the overall evidence gap.

Physicians who encounter patients already using MK-677 should focus on harm reduction rather than dismissal. Ordering monitoring labs, screening for co-use of hepatotoxic compounds, and counseling on stopping rules gives patients actionable information while preserving the clinical relationship. Patients who refuse to stop should receive at minimum quarterly LFTs and annual hepatic imaging.

The longest well-controlled trial remains 24 months at 25 mg/day with no liver-enzyme signal. [4] That single datum is the floor of the evidence, not the ceiling of safety assurance. Given that IGF-1 levels in MK-677 users routinely reach the upper quartile of the normal range or above, and given that the metabolic consequences of sustained GH exposure accumulate over years rather than months, a 24-month trial cannot rule out long-term hepatic risk.

Clinicians managing these patients should check a serum IGF-1 no less than every three months. An IGF-1 consistently above 300 ng/mL in an adult under age 50 warrants dose reduction or discontinuation regardless of whether transaminases are normal.